We would love to hear your thoughts about our site and services, please take our survey here.
Look at that share price, in the 360 pences, that’s seriously low. Back on March 9th we were on 462p and has anything negative happened to Aviva to warrant a 93p drop in share price, down 20%?
I am starting to hate investing in shares, I got lied to by an AIM company I was invested in, whilst here Aviva’s results were really good and yet 20% down in 5 months. Seriously what is the point having your money in shares when it can be safe in an ISA or premium bonds and guaranteed to make returns. There is no point to holding Aviva shares now that the interest rate can give decent returns, it was a different story when the interest rate was like 0.5% for so long.
When the FTSE 100 index reached over 8000 points I read experts saying that we had seen the last of 7500 for the FTSE 100. Now the index is really low, if experts couldn’t see this coming so soon then what hope does the average investor? But even when the FTSE was so high Aviva was not seeing any positive impact on the share price.
Add to that the capital gains limits have decreased significantly now, what incentive is there to buy shares? It’s a joke.
I see the whole insurance sector has struggled since March, it’s not just Aviva but I do feel that this is a very unfair share price given the latest results.
No doubt it will turn but once I have got my money back I’m out of this circus.
Tivman, well the last two share placings raised £10-£11m so I’m guessing that is what they will do again. Doesn’t seem much point raising just £5m if that’s only going to last 18 months to 2 years.
I’ll be surprised if for the 2023/2024 year that the costs will be less than £3.5m and EVG maybe able to hold off a share placing with less than £1m in the bank but surely not much less than that.
Flash, you took that snippet from the RNS regarding the Stalicla deal 10/10/2022:
· $0.5m upfront, $0.5m on completion of Phase 1 study (anticipated during Q2 2023). Milestone payments including $5m on grant of IND by the FDA (anticipated in late 2023).
It then was reported in the Half year report 08/12/2022:
Up to $6m in initial milestones to be received before end 2023.
And then in the Final results 07/06/2023:
Milestone payments from STALICLA collaboration expected during the year with up to $5.5m anticipated by 31 December 2024
There was no explanation why this went from ‘will be received before end of 2023” to now ‘anticipated by 31/12/2024’
I personally can’t believe they did that, saying $6m would be received by the end of this year when it’s not, that was why I bought in, thinking the company would be fully funded definitely until sometime in 2025.
How therefore can you trust that the money will be received in time to avert a share placing? Because right now the money in the bank must be about £3.5m. The last share placing was done when there was £1.5m in the bank.
Kev, you really should listen to KingAlf, Radar and I. We are like your guardian angels, the good guys on your shoulder trying to tell you don’t lose your money. The people who are positive about EVG are like the devil, the bad guy on your shoulder telling you to do it and take the risk and lose your money.
You’ll see in time that you should have listened to us.
KingAlf has been here for years, you really should show him more respect.
I’ve got to agree with Alf, my neighbour is autistic, I can’t imagine a broccoli tablet would cure him either. The brain is too complex and not possible to remedy so many conditions.
If the trials find that SFX-01 has no positive impact then Stalicla will soon pull the plug on the deal, just like Juvenesence did and where will that leave EVG?
In the RNS this week it said ‘Further analysis will be undertaken on this large and complex dataset to gain insight into the particular genes identified’. How long is that going to take? This share is known to go two months without any news, it happened between 22/03 to 26/05, 25/01 - 13/03, last year 22/07 - 29/09. It may be a slow news stream between now and the end of the year and that always sees the share price drop further.
Those who think this is nailed on to succeed are living in cuckoo land.
I honestly don’t think you need to be invested in this right now. If things go well you’ll be able to buy in and make good money.
King Alf, you’re not going to let Kev speak to you like that are you?
The share price here has been hammered in the last five months, down 18%, from 462p on March 9th to 379p yesterday yet the results are always solid. No matter what the market conditions Aviva perform really well. We didn’t even go up when the markets reached 8000 but have been pummelled when the markets have dropped. It’s about time the tide turned here.
On Target, how much money do you think EVG have in the bank right now? It was £5.0m at 31/03/2023. So about £3.5m-£3.7m? The last share placing in Feb 2021 was done with £1.5m in the bank.
EVG have said the $6m Stalicla payment next due is expected by the end of 2024. So how do you expect EVG to not issue a share placing sometime in the first half of 2024? How will they trade without money? You say that we are trolls, we are simply stating facts.
Kev, I liked your post at 08:13. You wrote:
MMs have no stock to sell, hence the spread. They aren’t having mine. I’m interested to see what a $160m payment from Stalicla does to the sp. GLA.
They have no stock to sell? Since the Juvenesence announcement there has been huge sells. And the Stalicla payment next due is $6m, you do realise that don’t you? And that’s not expected for over a year away.
Flash, yes you have summed up my thoughts exactly. I believe EVG have something in the SFX-01 drug and if only they had significant cash reserves I’d be happy to stick around but everything here takes forever and EVG don’t have forever.
I would have liked to have known why JuvLife called time with SFX-01 after 3 years, that seems strange. In the Q&A just a week before this news announced they were excited about this partnership and money incoming.
I am sure EVG will post some positive updates in the next 6 months but it will need to be either a huge contract signed (similar to the Stalicla deal) to raise the share price or some significant amount of money incoming to avert a share placing otherwise this is doomed in terms of a good investment opportunity. Will either happen? It’s not impossible but it is unlikely IMO.
If you’re already invested here then you’d like to think the share price can’t fall much lower between now and any announcement of a share placing, and any placing is surely over 6 months away so probably is best to hold for the time being. But IMO this has gone from an exciting share to an investment disaster. I’m so disappointed, I thought I found a share here that would make me loads of money, I’m sure many others did too otherwise they wouldn’t have invested. I’ll be watching with interest, time will tell.
Forgot to tag Strong sell.
£5m cash at 31/03/2023, spending for the year 01/04/2023 - 31/03/2024 probably around £3.5m with no income expected. Think you can expect a share placing around April 2024 to raise £10m. If they do at 2p there will be approx 775m shares in issue. What value do you think EVG can reach? Currently the market cap is £6.6m. If you think they can be worth £70m, with 775m shares in issue the share price would be only 9p a share if all goes really well. This goose is cooked unless there is a big change in fortunes. I’d never invest in this now given the dwindling cash, no income to come from Juvenesence and Stalicla money not expected until late 2024.
Trickymatters, ontarget, barf - when this really goes down the toilet when the next share placing happens, I think all three of you need to apologise to Alf, Radar and myself… and put some thought into the apology please. I’m appalled by the way you have spoken to us.
DSFiat, you don’t still have a million shares in EVG do you?
Tivman, I can’t find that piece of information. If you’re right then I stand corrected but even so $500,000 probably only funds a couple of months extra, it’s unlikely to avert a share placing.
Barf, you are fantasist, you put down this as a strong buy, you criticise people like Alf, radar and myself for posting critical comments about EVG, you state you have every confidence in a successful outcome here. You’re writing nonsense. EVG three years ago today was trading at 14.15p. If you bought £10,000 worth of shares at 14.15p three years ago it would today be worth £1725. You think people aren’t entitled to post critical comments of the business ? You say this is a strong buy? There will be no money coming into the company for the next year, not a sausage. A third share placing will happen next year in the space of four years, diluting the shares so much that it will become impossible for people to make their money back.
You need to realise that this is a messageboard about EVG shares and people are entitled to post their views. I get that you don’t believe in free speech and you should censor anyone who does not think the way you do but thank goodness the world doesn’t work like that.
Baf and Tivman, when you put it like that I see what you mean. I’m been very critical of EVG of late, of the finances, of the decisions made previously by the board to not raise far more money when the share price was higher, of posters here who are invested and don’t want negativity which may influence others to sell.
I’d like to take this opportunity to apologise… to absolutely nobody. It’s a messageboard about investing in shares for gods sake, stop being so ridiculous.
Kingalf, are you going to let him speak to you like that?
Tivman, you’re absolutely right, I could be wrong, after all I was wrong in investing here at 5.3p and 4.5p, although I feel like I know far more about EVG and their situation now compared to last October.
Don’t get me wrong, I think EVG have something in SFX-01, it’s not the drug I think is a problem it’s simply the cash flow. EVG has done a share placing in April 2019 and February 2021. It just seems inevitable another one is coming by next Spring.